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Abstract
Background: Thrombolysis with recombinant tissue plasminogen activator (rtPA) is an
established treatment in acute stroke. To prevent rethrombosis after rtPA therapy, secondary
anticoagulation with heparin is commonly performed. However, the recommended time-point and
extent of heparin treatment vary and are not well investigated.
Case presentation: We report a 61-year-old man who developed an acute global aphasia and
right-sided hemiparesis. Cranial CT was normal and systemic thrombolytic therapy with tPA was
started 120 minutes after symptom onset. Low-dose subcutaneous heparin treatment was initiated
24 hours later. Transthoracic echocardiography (TTE) 12 hours after admission showed slightly
reduced left ventricular ejection fraction (LVEF) but was otherwise normal. 48 hours later the
patient suddenly deteriorated with clinical signs of dyspnea and tachycardia. TTE revelead a large
left ventricular apical thrombus as well as a reduction of LVEF to 20 %. Serial further TTE
investigations demonstrated a complete resolution of the thrombus and normalisation of LVEF
within two days.
Conclusion: Our case demonstrates an intracardiac thrombus formation following rtPA
treatment of acute stroke, probably caused by secondary hypercoagulability. Rethrombosis or new
thrombus formation might be an underestimated complication of rtPA therapy and potentially
explain cases of secondary stroke progression.
Background
Recombinant tissue plasminogen activator (rtPA) is an
approved treatment option for acute ischemic stroke
within three hours of symptoms onset. It is well known
that reperfusion of ischaemic brain tissue, when per-
formed in a timely manner, improves clinical outcome
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ondary activation of coagulation cascades and inhibition
of endogenous fibrinolysis [3,4]. These hemostatic
changes might contribute to severe complications of rtPA
treatment such as vessel reocclusion or recurrent stroke.
Therefore, an adjuvant anticoagulation with heparin is
performed to prevent reocclusion in myocardial infarc-
tion [5] and after intra-arterial thrombolysis of the basilar
artery [6]. However, no studies or consensus exist regard-
ing early anticoagulation after systemic thrombolysis in
acute stroke.
We present a patient with acute ischaemic stroke who
developed a transient left ventricular apical thrombus
after systemic thrombolysis.
Case presentation
A 61-year-old man was admitted to the Emergency
Department immediately after he experienced global
aphasia and right-sided hemiparesis. The clinical diagno-
sis of acute cerebral ischaemia in the middle cerebral
artery (MCA) territory was made by a neurologist. A cra-
nial CT-scan showed no early signs of cerebral infarct and
no intracranial bleeding. Atrial fibrillation was recognised
on the initial ECG and an cerebral infarct of cardiac
embolic origin was assumed. The patient had no history
of stroke but suffered from coronary heart disease and sus-
tained an anterior cardiac wall infarction in the past. Fur-
ther known vascular risk factors were hypertension and
smoking. Even so, the patient took no medication at the
time of admission.
Thrombolysis with 70 mg rt-PA (0.9 mg/kg) was started
two hours after the onset of symptoms. The neurological
status during and after rt-PA treatment remained
unchanged. Transthoracic echocardiography (TTE) per-
formed 12 hours after initiation of thrombolytic therapy
revealed a moderately reduced left ventricular systolic
function (ejection fraction: 41%), left ventricular regional
dyssynergy, and no intracardiac thrombus.
The D-Dimer antigen plasma concentration as a marker of
coagulation activation was raised 24 hours after rt-PA
treatment and showed a tendency to normalisation dur-
ing the following days.
Extracranial Duplexsonography revealed moderate arteri-
osclerotic plaque formation in the carotid bulb on both
sides but no hemodynamic stenosis of the carotid and ver-
tebral arteries. Using transcranial duplexsonography a
severe stenosis was found in the proximal segment of the
left middle cerebral artery. No diabetes or hyperlipidae-
mia were diagnosed. Cerebral MRI, twenty-four hours
after lysis revealed a cortical infarct with a clinically
asymptomatic haemorrhagic transformation in the left-
sided MCA territory. Antithrombotic treatment with sub-
cutaneous low-dose heparin (Dalteparin 2/d) was initi-
ated 24 hours after thrombolysis. The fluid balance was
continuously monitored and kept net 0 ml/24 hours to
avoid fluid overload.
On the 3rd day after admission, the patient developed
acute dyspnea, tachypnea, tachycardia, and an elevated
blood pressure. Acute myocardial infarction was excluded
on the basis of ECG and blood tests (CK, CK-MB, Tro-
ponin were normal). A CT-scan detected no pulmonary
embolism, but massive bilateral pleural effusion. TTE
revealed an apical thrombus measuring 2.0 × 2.0 cm in
the left ventricle (figure 1) with left ventricular ejection
fraction reduced to 20%. The thrombus, was fixed to the
hypokinetic anteroseptal wall. Serial TTE performed two
days later revealed complete resolution of the thrombus
and hypokinesia; with a left ventricular ejection fraction
of 40%. In the mean time the patient recovered from the
acute cardiac decompensation. The neurological clinical
picture remained stable during the acute phase with a
slight improvement of aphasia and hemiparesis within
the following 5 weeks.
Discussion
Systemic rt-PA thrombolysis in acute stroke has been
implemented into daily clinical practice during the last
decade. The treatment within three hours of stroke
appears to be effective in reducing the neurological deficit
[1,7]. However, the use of rtPA therapy remains limited
due to the narrow time-to-treatment windows and the
potential complications of intracranial haemorrhage [7].
The optimal time-point of anticoagulation after systemic
thrombolysis is unclear due to a lack of evidence. In
accordance with the NINDS-protocol anticoagulation is
interdicted within 24 hours after thrombolysis [1]. Also,
latest guidelines for early stroke management recommend
no antithrombotic therapy within 24 hours after applica-
tion of rt-PA although there is increasing evidence for ves-
sel reocclusion in about one third of the patients [8].
However, in clinical practice the use of anticoagulative
agents seems to be much more heterogeneous [9].
Some authors have reported a significantly higher inci-
dence of parenchymal haematomas if thrombolysis was
immediately followed by intravenous or subcutaneous
heparin administration [10]. However, recent analyses
have shown that full-dose intravenous anticoagulant
treatment within 24 hours does not increase the incidence
of parenchymal hemorrhage [9].
rt-PA has a short biological half-life of 8–12 minutes but
alters the physiological balance between coagulation and
anticoagulation for a longer time period [11]. After dis-
continuation of rtPA infusion several mechanisms,Page 2 of 5
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tus have been discussed. For instance, the activation of
plasminogen activator inhibitor-1, resulting in suppres-
sion of endogenous fibrinolysis [4], the increase of
thrombin generation and activity [3], the increase of
thrombin-antithrombin-III-complex levels [12] or the
induction of hypoperfusion in ischaemic brain tissue
[11]. The procoagulant response to rt-PA has been shown
to persist up to 72 hours [3].
Otherwise, clinical studies of fibrinolytic therapy in myo-
cardial infarction show, that early heparin treatment start-
ing immediately after thrombolysis significantly decreases
the risk of cardiac vessel reocclusion [5]. The capacity to
attenuate the increased coagulation activity seems to be
similar, regardless if low-molecular-weight or unfraction-
ated heparin is used [13]. In stroke patients with an occlu-
sion in the posterior cerebral circulation undergoing intra-
arterial thrombolysis, heparin treatment is also known to
reduce the rate of early reocclusion [6].
In our patient, treated with low dose heparin, an apical
thrombus developed within 72 hours after thrombolytic
therapy, strongly suggesting a causal relationship of sec-
ondary hypercoagulability and thrombus formation. The
patient's history and risk profile suggests an increased risk
for cardiac events [14]. We postulate, that he developed an
acute coronary syndrome (dyspnea and tachycardia) on
the basis of the pre-existing cardiac disease with kinetic
disturbance which subsequently enabled the formation of
Cardiac duplex ultrasound image (4-chamber view), obtained 2 days after thrombolysis showing the thrombus attached to left ventricular apex (a row)Figure 1
Cardiac duplex ultrasound image (4-chamber view), obtained 2 days after thrombolysis showing the thrombus attached to left 
ventricular apex (arrow).Page 3 of 5
(page number not for citation purposes)
Cardiovascular Ultrasound 2005, 3:14 http://www.cardiovascularultrasound.com/content/3/1/14a ventricular thrombus – promoted by the risk factors
hypercoagulability, atrial fibrillation and previous
myocardial infarction [15]. The transient increase of D-
Dimer probably indicates the state of hypercoagulability
after rt-PA treatment [3]. The low-dose heparin therapy in
our patient was not sufficient to prevent thrombus devel-
opment although a number of studies have shown that
sufficient systemic anticoagulation with heparin is able to
do so [16].
Coronary angiography was not performed, considering
the cerebral state of the patient and the observation that
repeated ECGs were normal and cardiac enzymes not ele-
vated. The clinical status stabilised spontaneously and the
cardiac thrombus resolved within two days without initi-
ation of a specific therapy, further supporting the hypoth-
esis of a temporary status of hypercoagulation after
thrombolysis.
Another hypothesis for the temporary cardiac detoriation
in our patient could be an acute neurogenic stunned myo-
cardium. This phenomenon is described as sudden,
reversible left ventricular dysfunction with abnormal left
ventricular wall motion and reduced ejection fraction.
Levels of creatine kinase MB and troponin may be ele-
vated and ECG alterations as depression or elevation of
the ST segment or T wave inversion can be observed. How-
ever, acute neurogenic myocardial stunning has so far
only been reported after subarachnoid hemorrhage [17-
20] and in isolated cases of subdural hematoma [21] and
Guillain-Barré syndrome [22]. We found no evidence in
the literature for acute neurogenic myocardial stunning
after stroke. In addition, our patient suffered from coro-
nary artery disease whereas neurogenic myocardial stun-
ning has been reported in patients without cardiac
disease. Finally, the cardiac failure in our patient occurred
on the 3rd day and not directy after stroke which makes the
diagnosis of neurogenic stunned myocardium further
unlikely [17,20,21].
In summary, our case demonstrates an intracardiac
thrombus formation following rtPA treatment of acute
stroke, probably caused by secondary hypercoagulability.
Rethrombosis or new thrombus formation might be an
underestimated complication of rtPA therapy and poten-
tially explain cases of secondary stroke progression. Early
systemic anticoagulation with heparin might reduce the
risk of rethrombosis but also increase the risk of a bleed-
ing complication. Systematic studies concerning the inci-
dence of thrombus formation after rtPA therapy and the
effects of different post-thrombolysis anticoagulation
strategies are required to assess the clinical relevance of
the discussed secondary hypercoagulability. Closed
echocardiographic monitoring in stroke patients treated
with systemic thrombolysis might be useful for early
detection of the described potential cardiac complications
especially because repeated measurement of ECG and car-
diac enzymes alone might fail.
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